chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I did have (starting after midnight) - a fever and body aches and joint pain, chills and headaches, arm pain. I had nausea a couple of times a couple of days after but I hadn't eaten a whole lot. 15th I still felt it. I think my fever was gone on 15th.  I had fatigue for a few days. Saturday or Sunday, I had a fever again and that time with nausea and with muscle aches. I have had a rash that I noticed a couple of days after the vaccine (the second time that I had the fever) - it was like a rash  I had when I was on a certain birth control - I still have the rash - it is all over legs. It is itchy sometimes. It hasn't been itchy for the last couple of days so maybe it's starting to go away. I saw my doctor on either Saturday or Sunday. It was an acupuncture treatment-with  general practitioner who does acupuncture. I had acupuncture for my headaches specifically. It helped with the general ongoing headache that I had had since the night I first started having symptoms.
Client presented health department for Menactra immunization and PPD, given 1 hour apart; following PPD, summoned to waiting room to assist; client reclined in chair not responding to name; breathing without difficulty; client's extremities became rigid; hyper-extended head and repeatedly thrust head against wall; episode lasted approximately 5-8 seconds followed by 10-15 seconds of semi-conscious responses; after episode, client able to sip small amounts of water and respond appropriately to questions; client escorted, via wheelchair, to exam room to rest while awaiting transportation to local ER for evaluation.
Pneumovax injected 11:30 am 11/2/07. Fever, hives, extreme swelling,pain in the entire left arm and left side of back.
Minor  "frozen shoulder" like symptoms in my surgically repaired left shoulder. Significantly limited range of motion (at the worst only about 20 degrees of movement) and joint pain (6/10 left shoulder). Symptoms persisted for approximately 10 days with improvement each day following onset. I used physical therapy exercises previously used in should rehabilitation. I was able to find some anecdotal evidence for this sort of reaction. Had problems persisted longer or gotten worse I would have sought medical treatment. I wanted to add my report as collateral information for possible future research into this sort of reaction.
About 2 days after receiving the first dose of Japanese Encephalitis vaccine and first dose of Rabies, client began having intermittent, generalized hives.  BENADRYL as needed.
I did not have an adverse reaction to the vaccine. I tested positive for COVID-19 in 12/2022. I felt like I had a mild case of flu with a headache. I contacted my doctor and got a prescription for Paxlovid. I tolerated the medication without any complications. As of today, I do not have any lingering COVID-19 symptoms.
Bilateral cataracts; This is a Non-Interventional study (solicited report) based on the information received by Pfizer . (MFR Control No. # 21K-163-3911539-00). A male patient of an unspecified age received first dose of BNT162B2 (BNT162B2) intramuscular on 26Feb2021 (Batch/Lot number was not reported) as 1ST DOSE, SINGLE, and second dose intramuscular on 27Mar2021 (Batch/Lot number was not reported) as 2ND DOSE, SINGLE for covid-19 immunization and adalimumab (HUMIRA), subcutaneous from Sep2014 (Batch/Lot number was not reported) and ongoing,  (40 mg,1 in 2 wk) for rheumatoid arthritis. Medical history included non-smoker, abstains from alcohol, chronic obstructive pulmonary disease, arthritis, diuretics, high cholesterol, high blood pressure and neuropathy from an unknown date and unknown if ongoing. Concomitant medications included budesonide, formoterol fumarate (SYMBICORT) taken for chronic obstructive pulmonary disease, methotrexate (METHOTREXATE) taken for arthritis, prednisone (PREDNISONE) taken for arthritis, furosemide (FUROSEMIDE) taken for polyuria, lovastatin (LOVASTATIN) taken for blood cholesterol increased, isosorbide (ISOSORBIDE) taken for hypertension, clopidogrel (CLOPIDOGREL) taken for hypertension, metoprolol (METOPROLOL) taken for hypertension, potassium (POTASSIUM) taken for an unspecified indication, hydrochlorothiazide (HYDROCHLOROTHIAZIDE) taken for hypertension, folic acid (FOLIC ACID) taken for arthritis, aspirin [acetylsalicylic acid] (ASPIRIN [ACETYLSALICYLIC ACID]) taken for hypertension, gabapentin (GABAPENTIN) taken for neuropathy peripheral and ipratropium bromide, salbutamol sulfate (COMBIVENT) taken for chronic obstructive pulmonary disease. The patient experienced bilateral cataracts on 30Mar2021. It was reported that on 27Apr2021, the patient underwent out patient cataract surgery on left eye  and on 11May2021 on right eye, due to blurry vision. The symptom blurry vision  was improved. The patient underwent lab tests and procedures which included ophthalmological examination: cataract on Mar2021 (Confirmed patient has cataract that causes blurry vision in left and right side of the eye).  The action taken for adalimumab was unknown.  Therapeutic measures were taken as a result of bilateral cataracts. Outcome of the event was recovering. Causality for HUMIRA 40MG/0.4ML(ADALIMUMAB): The reporter's causality for the event(s) of CATARACT ON LEFT AND RIGHT SIDE OF EYE with HUMIRA 40MG/0.4ML(ADALIMUMAB) was no reasonable possibility.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.; Sender's Comments: The reported cataract is likely an intercurrent medical condition and unrelated to BNT162B2. Case will be reassess once additional information becomes available.
Itching in my scalp; heat bothers it more that the cold weather; the second dose is when it is really been acting up; This is a spontaneous report from a contactable consumer (patient). A 78-year-old female patient received second dose of BNT162B2 (COVID-19 VACCINE PFIZER, Solution for injection, NDC/UPC number: Unknown, Expiry date: Unknown) via an unspecified route of administration on 28Jan2021 (at the age of 78-year-old) (Lot number: EL9265) as single dose for Covid-19 immunisation. The patient's medical history included hypertension and heart attack. Concomitant medications included clopidogrel bisulfate (PLAVIX) at 75 mg, metoprolol and benazepril. About the concomitant medication, consumer stated, "she wanted to say it was NORVASC, but did not want to tell wrong. That was going to be amlodipine besylate and that was the 2.5 mg (further not clarified)". The patient previously took first dose of BNT162B2 (COVID-19 VACCINE PFIZER) (at the age of 77-years-old) on 07Jan2021 (Lot number: EK9231) as single dose for Covid-19 immunisation and experienced itching in scalp. It was reported that, itching in scalp; heat bothered it more that the cold weather in Jan2021. Consumer stated, "she had both the shots. One of the side effects said itching. It was settled in scalp. She had itching in scalp, so, was trying to find out if there was anything that she could put on it to stop the itching". Consumer stated, "itching in scalp was about 4 days after the first but it was very lite was not aggravating or irritated or nothing but with the second dose is when it is really been acting up. Heat bothers it more that the cold weather. Cold weather does not seem to itch that much". Regarding lab data, consumer stated, "Not in the last 2 weeks. But they went every three months. They both had the same medical doctor, the cardiologist". She did not take any treatment in response to the event. Outcome of the events was unknown.  Follow-up attempts completed. No further information expected.
Information has been received from a healthcare worker referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concomitant medication were not provided. On an unknown date after 07-OCT-2016, the patient was vaccinated with improperly stored PROQUAD (rHA, lot # M031567, expiration date 24-DEC-2017, 0.5 ml, subcutaneous) for prophylaxis. No adverse effects were reported. The excursion temperature included higher than 5 Fahrenheit degree but lower than 14 Fahrenheit degree for 8 hours and 30 minutes and higher than 14 Fahrenheit degree but lower than 46 Fahrenheit degree for 30 minutes. There was no previous excursion. Data logger was involved. No product quality complaint was involved. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1701USA003754.
FEELING DOWN; FEELING SICK; RASH; This spontaneous report received from a patient concerned a 37 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced feeling down, feeling sick, and rash. Treatment medications (dates unspecified) included: dextromethorphan hydrobromide/doxylamine succinate/ephedrine sulfate/ethanol/paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the feeling down, feeling sick and rash was not reported. This report was non-serious.
Local reaction: swelling/redness approximately 1" x 1.5".  R arm feels weak/heavy. Employee noticed the previous symptoms evening of 4/28/2020 and have continued into today. Employee started experiencing nausea, unbalanced, dizziness 4/29/2020 at approximately 8 am.
BLOOD CLOT IN LEFT LEG; LEFT LEG CALF PAIN; This spontaneous report received from a patient concerned a 78 year old Asian, Not Hispanic or Latino male. The patient's weight was 220 pounds, and height was 67 inches. The patient's past medical history included stent (unknown where stent was placed), and concurrent conditions included non alcohol user, and non smoker. The patient had no known drug allergies and no any drug abuse / illicit drug use. The patient was previously treated with Clopidogrel bisulfate for drug used for unknown indication.  The patient received Covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805031, and expiry: UNKNOWN) dose was not reported, 1 total administered on 18-MAR-2021 to left arm for prophylactic vaccination. Concomitant medications included amlodipine, metformin, metoprolol, and vitamin b complex all for drug used for unknown indication. On 28-MAR-2021, the subject experienced left leg calf pain. Patient reported that he experienced left leg pain below calf muscle and went to hospital and was further diagnosed with blood clot in left leg on 16-APR-2021. He was on Plavix and asked to stop Plavix on 16-APR-2021 by physician and placed on Eliquis 10 mg for the first 7 days twice a day and then 5 mg once a day for blood clot in left leg as treatment administered and with further concern to physician. He had appointment to hematologist for further follow up on 26-APR-2021. Laboratory data included: Diagnostic ultrasound (NR: not provided) Blot clot to left lower leg on 16-APR-2021. The action taken with Covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from left leg calf pain, and blood clot in left leg. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: This is a 78 year old male patient,  who experienced left leg calf pain 10 days after receiving the Janssen COVID-19 vaccine on his left arm. 29 days after receiving the vaccine, patient sought consult for the left leg pain and was further diagnosed with blood clot on the left leg by diagnostic ultrasound. Patient's weight is 220 pounds and has a height of 67 inches. Patient is non smoker and does not take alcoholic beverages. Patient has no known history of drug allergies or drug abuse. Past medical history include having stent placed on him but he could not recall where the stent was placed. Patient was on Clopidogrel bisulfate but was asked to stop on the day he was diagnosed with the blood clot. Other concomitant medications include: amlopidpine, metformin, and vitamin B complex,. Indication for all medications being taken is unknown.  Age and obesity (BMI = 34.5 per weight and height provided) are known risk factors for developing blood clot in the lower leg. Having a stent and concomitant medication suggest a cardiac problem. Based on the available information and considering the temporal relationship, the events of left leg calf pain and blood clot are assessed as indeterminate per WHO causality classification of adverse events following immunization.
muscle aches; freezing; not feeling well; fever; nausea; fatigue; patient was prescribed Shingrix by her physician; inappropriate age at vaccine administration; bled at the injection site; pain at the injection site/ soreness at the injection site; bump at the injection site; knuckle at the injection site; problems sleeping; This case was reported by a pharmacist via call center representative and described the occurrence of injection site hemorrhage in a 30-year-old female patient who received Herpes zoster (Shingrix) (batch number 23JK5, expiry date 13th April 2019) for prophylaxis.   The patient's past medical history included shingles.   On 1st May 2019, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 1st May 2019, less than a day after receiving Shingrix, the patient experienced injection site hemorrhage, injection site pain, injection site swelling, injection site lump, sleep problem, off label use and inappropriate age at vaccine administration. On 2nd May 2019, the patient experienced muscle pain, feeling cold, feeling unwell, fever, nausea and fatigue. On an unknown date, the outcome of the injection site hemorrhage, injection site swelling, injection site lump and sleep problem were recovered/resolved and the outcome of the injection site pain, muscle pain, feeling cold, feeling unwell, fever, nausea and fatigue were not recovered/not resolved and the outcome of the off label use and inappropriate age at vaccine administration were unknown.   It was unknown if the reporter considered the injection site hemorrhage, injection site pain, injection site swelling, injection site lump, sleep problem, muscle pain, feeling cold, feeling unwell, fever, nausea and fatigue to be related to Shingrix.  Additional details were provided as follows: The patient was prescribed Shingrix by her physician. The patient bled at the injection site, she had little bump that came up immediately after having the injection. It was a knuckle at the injection site and patient also experienced pain and soreness at the injection site. The patient reported having problems sleeping last night and woke up with muscle aches, feeling like freezing and not feeling well. At the day of reporting, the patient complained of having soreness at the injection site and also complained low grade fever, nausea and fatigue.
This case was reported by a healthcare professional and described the occurrence of injection site redness in a female subject of unspecified age who was vaccinated with ENGERIX B (GlaxoSmithKline). On an unspecified dates the subject received 1st dose and 2nd dose of ENGERIX B (details unknown). On 03 April 2011 the subject received 3rd dose of ENGERIX B (10 mcg, left arm). On an unspecified date at an unknown time after the 1st dose ENGERIX B, the subject experienced injection site redness, swelling injection site, injection site pruritus and hotness at injection site. The events resolved on an unspecified date without intervention. After the next vaccination (2nd dose) with ENGERIX B the events recurred. On 03 April 2011, less than one day after vaccination with ENGERIX B (3rd dose), the subject experienced injection site redness, swelling injection site, injection site pruritus and hotness at injection site. The subject was treated with ice (Ice pack). At the time of reporting the events were unresolved. The healthcare professional considered the events were probably related to vaccination with ENGERIX B. Follow-up information was received on 03 May 2011. It was reported that the events were all resolved and that they were probably related to treatment with ENGERIX B.
Simple partial seizures started almost 8 days after 1st Moderna shot, and have continued ever since.  I have grand-mal, and never simple partial. I'm taking antiseizure medicine, which was increased, but they continue.  A low grade fever of 99.0, the highest was 99.4, for two weeks. Rashes, red, itchy and raised, on my wrists started after 2nd shot, alternating on and off. One time on my neck and onto face. Then a rash on my right upper arm,  had stopped about 5 days ago. but today a new one on my wrist started. Pain in my arms on and off, and new pain started today in my left arm , before the rash started.
It was reported that a 33 year old female pt received TD ADS ADULT, lot number U0817AA, given IM in the left deltoid and DEPO PROVERA, given IM in the left deltoid on 1/30/03. The vaccinations were given approximately one inch apart. On 2/1/03, pt went to the hospital ER, where they treated her with IV antibiotics. On 2/2/03, pt went to another ER where she was admitted. It was reported that the pt is still there. Pt is said to have cellulitis. It is unknown if pt recovered. Pt had no illness at the time of vaccination. Reported on 02/20/2003: "From follow-up #1 received on 02/06/2003, it was reported that the patient developed "cellulitis of arm" after the Tetanus and Depo-Provera (lot number JP1204) injection.  No additional information was provided.  Follow up on 07/07/2003: "From additional information received on 06/25/2003 from the reporter, it was stated that there is no new medical information.  The "patient returned to her previous clinic and has not been back since.  We did not receive the hospital discharge summary on this patient".  No further information is anticipated, this case is considered closed."  Follow up on 12/05/03: "From follow up #1 received on 02/06/03, it was reported that the pt developed "cellulitis of arm" after the Tetanus and Depo-Provara (Lot # JF1204) injection. No additional information was provided."
This spontaneous report as received from a nurse refers to a 14 year old female patient. The patient was not pregnant. The patient's pertinent medical history was none. The patient had no known drug allergies. On 13-JAN-2014, the patient was vaccinated with second dose of GARDASIL (dose, frequency and route were not reported) (lot # J014295 and expiry date: 11-AUG-2016). Concomitant medications were none. Approximately in January 2014 (reproted as a week later on an unspecified date), the patient fainted in the bathroom before breakfast. The patient also experienced shakiness in her one hand on an unspecified date. The patient did not sought medical attention and no treatment was given for the events. The outcome of fainted in the bathroom before breakfast and shakiness in her one hand was reported as recovered on an unspecified date. The causality of the events was not reported. No product quality complaint (PQC) was reported for GARDASIL. Additional information has been requested.
experienced redness at the injection site, swelling and pain; redness at the injection site; swelling at the injection site; pain at the injection site; Initial information was received on 14-Feb-2020 regarding an unsolicited valid non-serious case received from a pharmacist.  This case involves a 67 years old female patient who experienced redness at the injection site, swelling and pain (vaccination site inflammation with vaccination site erythema, vaccination site pain and vaccination site swelling), while she received vaccines INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT].  The patient's ongoing medical condition included allergy to thimerosal.  Medical history, past medical treatment, past vaccination and family history were not provided.   The patient received concomitant vaccination of VARICELLA ZOSTER VACCINE in left arm on 28-Oct-2019.  On 28-Oct-2019, the patient received a 0.5 mL dose of suspect INFLUENZA QUADRIVAL A-B VACCINE (lot QSAA1965, Expiration date- 14-Jun-2020) via an unknown route in the left arm for prophylactic vaccination.  On 28-Oct-2019, the patient developed a non-serious redness at the injection site, swelling and pain (vaccination site inflammation) as diagnosis and (vaccination site erythema), (vaccination site swelling), (vaccination site pain) as symptoms after a couple of hours following the administration of INFLUENZA QUADRIVAL A-B VACCIN.  Laboratory data was not provided.  Final diagnosis was vaccination site inflammation.  It was not reported if the patient received any corrective treatment.  At the time of report, the outcome of the events was unknown.
Systemic: Fainting / Unresponsive-Mild, Systemic: Tinnitus-Mild, Systemic: Weakness-Mild, Additional Details: Patient fainted after medication administration. blood pressure was taken and was low. patient drank some water and remained laying down until she felt better. elevated her legs to keep help with her blood pressure. Patient was fine after about 20 minutes
Hospitalization;  COVID-19 positive (9.8.21);  fully immunized  Admission Date: 9/8/2021 Discharge Date: 9/11/2021 Discharge Disposition:  home health care svc      Active Issues Requiring Follow-up:  PCP , will need help on procuring interferon beta  DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Generalized weakness [R53.1]   HOSPITAL COURSE: Patient is a 82 y.o. female with PMH of multiple sclerosis, neurogenic bladder s/p chronic Foley, hyperlipidemia, hypertension, DVT, and CVA with chronic left-sided weakness who presented to the ED 9/8 for generalized weakness.  The patient is wheelchair/bed bound as a result of MS and previous CVA.  Over the past 3 weeks she noted increasing generalized weakness particularly of her bilateral upper extremities. This had been much worse within the last week.  She was concerned that this was related to MS because she  stopped taking her q48hr Interferon beta in July because it was too expensive. Her acute on chronic weakness was felt to be due to progression of MS off of Interferon beta and COVID. PT rec discharge home with assist which CM ensured was in place prior to discharge. SLP evaluated and recommended dysphagia diet. No hypoxemia, imaging findings, or significant respiratory symptoms to suggest COVID pneumonia during admission. She had diarrhea on presentation that self resolved. She had asymptomatic pyuria and was given Ceftriaxone in the ED, urine cultures showed mixed flora antibiotics were not continued during admission.
Pain in upper left arm that radiates down to hand. Unable to secure bra, seat belt, reach for anything above my head or sleep on that side.  This started after second vacine on Fed 5 2021 at same location, same arm also Pfizer